

HE Dr. Nusratullo Faisullaev Salimzoda  
The Minister of Health  
Ministry of Health  
Shevchenko 69  
Dushanbe 734000  
The Republic of Tajikistan

15 December 2016

***Decision Letter: Request for 2017 Renewal of Gavi vaccine support***

Your Excellency,

I am writing in relation to Tajikistan's request for renewal of the New Vaccine Support (NVS) for Pentavalent Vaccine and Rotavirus Vaccine that was reviewed by Gavi Managing Directors' Review on 18 of October 2016.

Following the recommendations made by the Managing Directors' Review, I am pleased to inform you that Gavi has **approved** Tajikistan's request to renew Gavi vaccine support for 2017, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Financial and Programmatic information –Support for Pentavalent Vaccine

Appendix B: Financial and Programmatic information –Support for Rotavirus Vaccine

Appendix C: Financial and Programmatic information –Support for Injection Safety Devices

Appendix D: Recommendations of the Managing Directors' Review

Please do not hesitate to contact my colleague Ms Nilgun Aydogan at [naydogan@gavi.org](mailto:naydogan@gavi.org) if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman  
Managing Director, Country Programmes

cc: The Minister of Finance  
The Director of Medical Services  
Director Planning Unit, MoH  
The EPI Manager  
WHO Country Representative  
UNICEF Country Representative  
Regional Working Group  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

**Decision Letter  
Tajikistan - Support for Pentavalent Vaccine**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> The Republic of Tajikistan			
<b>2. Grant number:</b> 17-TJK-04a-X			
<b>3. Date of Decision Letter:</b> 15/12/2016			
<b>4. Date of the Partnership Framework Agreement:</b> 07/11/2012			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2008 - 2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	<b>2008-2016</b>	<b>2017</b>	<b>Total<sup>2</sup></b>
<b>Programme Budget (US\$)</b>	14,576,811 <sup>3</sup>	1,362,500	15,939,311
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2008-2016</b>	<b>2017</b>	
Number of Pentavalent vaccines doses		738,600	
<b>Annual Amounts (US\$)</b>	<b>14,576,811<sup>5</sup></b>	<b>1,362,500</b>	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable.			
<b>14. Co-financing obligations:</b> Reference code: 17-TJK-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2017</b>		
Number of vaccine doses	121,300		
Value of vaccine doses (US\$)	215,182		
<b>Total co-financing payments (US\$) (including freight)</b>	<b>224,000</b>		
<b>15. Operational support for campaigns:</b> Not applicable			
<b>16. Additional reporting requirements:</b> Not applicable			
<b>Reports and other information</b>	<b>Due dates</b>		
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any	15 May 2017		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.


<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

proposed changes in presentation or minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*: as specified in the Appendix F	
<b>18. Other conditions:</b> Not applicable.	

Signed by,



**On behalf of Gavi**  
 Hind Khatib-Othman  
 Managing Director, Country Programmes  
 15 December 2016

**Decision Letter**  
**Tajikistan - Support for Rotavirus Vaccine**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> The Republic of Tajikistan				
<b>2. Grant number:</b> 1517-TJK-13b-X				
<b>3. Date of Decision Letter:</b> 15/12/2016				
<b>4. Date of the Partnership Framework Agreement:</b> 07/11/2012				
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine				
<b>6. Vaccine type:</b> Rotavirus				
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule				
<b>8. Programme duration<sup>6</sup>:</b> 2015 - 2018				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	<b>2015-2016</b>	<b>2017</b>	<b>2018</b>	<b>Total<sup>7</sup></b>
<b>Programme Budget (US\$)</b>	2,585,500 <sup>8</sup>	1,187,500	1,169,500	4,942,500
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>9</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2015-2016</b>	<b>2017</b>		
Number of Rotavirus vaccines doses		526,500		
<b>Annual Amounts (US\$)</b>		<b>2,585,500<sup>10</sup></b>		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>13. Self-procurement:</b> Not applicable.				
<b>14. Co-financing obligations:</b> Reference code: 1517-TJK-13b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2017</b>		<b>2018</b>	
Number of vaccine doses	70,500		78,000	
Value of vaccine doses (US\$)	151,199			
<b>Total co-financing payments (US\$) (including freight)</b>	<b>\$155,500</b>		<b>173,500</b>	
<b>15. Operational support for campaigns:</b> Not applicable				

<sup>6</sup> This is the entire duration of the Programme.

<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>8</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>9</sup> This is the amount that Gavi has approved.

<sup>10</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>16. Additional reporting requirements:</b>	
<b>Reports and other information</b>	<b>Due dates</b>
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable.	
<b>18. Other conditions:</b> Not applicable.	

Signed by,



**On behalf of Gavi**  
 Hind Khatib-Othman  
 Managing Director, Country Programmes  
 15 December 2016



**Decision Letter**  
**Tajikistan - Support for Injection safety devices**

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> The Republic of Tajikistan		
<b>2. Grant number:</b> 17-TJK-32a-X		
<b>3. Date of Decision Letter:</b> 15/12/2016		
<b>4. Date of the Partnership Framework Agreement:</b> 07/11/2012		
<b>5. Programme title:</b> Injection safety devices <sup>11</sup>		
<b>6. Programme duration<sup>12</sup>:</b> 2017		
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)		
	<b>2017</b>	<b>Total<sup>13</sup></b>
<b>Programme Budget (US\$)</b>	54,000	54,000
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>14</sup>		
<b>TOTAL immunisation supplies to be purchased with Gavi funds in each year</b>		<b>2017</b>
Number of AD syringes		1,061,400
Number of safety boxes		11,700
<b>Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)</b>		<b>54,000</b>
<b>Immunisation supplies to be purchased with Gavi funds in each year, <u>by type of support</u></b>		
<b>New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID</b>		<b>2017</b>
Number of AD syringes		918,500
Number of safety boxes		10,125
<b>Annual Amounts for immunisation supplies for Vaccine (US\$)</b>		<b>46,500</b>
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine</b>		<b>2017</b>
Number of AD syringes		142,900
Number of safety boxes		1,575
<b>Annual Amounts for immunisation supplies for Vaccine (US\$)</b>		<b>7,500</b>
<b>9. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>10. Self-procurement:</b> Not applicable.		
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.		

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
15 December 2016

<sup>11</sup> This does not include vaccines.

<sup>12</sup> This is the entire duration of the Programme.

<sup>13</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>14</sup> This is the amount that Gavi has approved.

## Appendix D

The MDs, following their deliberations:

- Recommended to the CEO:

<b>Programme</b>	<b>Recommendation</b>	<b>Period</b>	<b>Indicative amount to be paid by Gavi</b>
NVS – Pentavalent 1 dose liquid	Extension	2017	US\$ 1,362,500
NVS – Rotavirus 2 dose	Renewal	2017	US\$ 1,187,500

